Skip to main content
. Author manuscript; available in PMC: 2018 Nov 28.
Published in final edited form as: J Control Release. 2017 Sep 28;266:156–165. doi: 10.1016/j.jconrel.2017.09.034

Figure 6.

Figure 6

Splenocytes were harvested on day 25 from EAE mice treated in vivo with components of co-delivery treatment, IFA with DEX + PLP. Splenocytes were incubated for 120 hours with or without 25 μM PLP rechallenge. The cells were then stained with antibodies for CD3 (Alexa Fluor 488), CD19 (Alexa Fluor 647), and CD11c (Pacific Blue) and analyzed by flow cytometry. Cell populations were determined for A.) T-cells (CD3+), B.) Dendritic Cells (CD11c+), C.) B-cells (CD19+) and D.) autoimmune associated B-cells (ABCs, CD19+CD11c+) as a percentage of the total cell population. E.) The percentage of CD11c+ cells out of the CD19+ cell population was also determined. F.) Gating for CD19+ B-cells is shown for both IFA and IFA with DEX + PLP, without antigen rechallenge. (n= 3-5 per group, * p< 0.05 comparing different treatment groups, # p<0.05 for 25 μM PLP versus no PLP for the same treatment, Black bars indicate 25 μM PLP and Gray bars indicate no PLP rechallenge)